MYCENAX

NEXT GENERATION ADC

(Antibody-Drug Conjugates)



MYCENAX

Next Generation ADC

Advanced Technology: Innovations and Value of Multi-Arm & Dual-Payload Linker in ADC Applications

As a CDMO company committed to leveraging cutting-edge technologies, we have successfully applied Mycenax's Multi-Arm and Dual-Payload Linkers in ADC development, bringing new possibilities and added value for next-generation ADCs.

The Multi-Arm Linker is designed to enhance drug loading capacity, while the Dual-Payload Linker represents a critical innovation for addressing ADC drug resistance.

By harnessing the synergistic or additive effects of dual payloads, this technology can overcome tumor heterogeneity and drug resistance, paving the way for more effective cancer therapies.

Traditional ADC

Multi-arm ADC



Figure 1. Innovative multi-arm ADC Designs

- Overcome the DAR-2 limitation of traditional site-specific ADCs, achieving DAR 4, 6, and 8.
- Enable low-toxicity payloads for ADC applications in cancer therapy.

Dual-payload ADC



Figure 2. Innovative dual-payload ADC Designs

- Achieves synergistic or additive effects, overcoming tumor heterogeneity and drug resistance.

Mycenax has successfully implemented the linker in two site-specific conjugation technologies: engineered cysteine-based conjugation and enzymatic conjugation. Both technologies demonstrated conjugation efficiency for dual-payload ADCs comparable to that of traditional ADCs, confirming that Mycenax's linker maintains reactivity equivalent to traditional linkers. Notably, the complex dual-payload linker did not compromise reactivity.



Figure 3. Conjugation process monitoring of engineered cysteine-based conjugation

(A) Traditional ADC:

- Average DAR: 1.6 MMAE
- Conjugation efficiency: 80%

(B) Mycenax's Dual-Payload ADC:

- Average DAR: 1.6 MMAE+ 1.6 DXD
- Conjugation efficiency: 80%

(A) A mAb (Thiomab) was conjugated with a traditional linker-MMAE, yielding an ADC with an average Drug-to-Antibody Ratio (DAR) of 1.6.
(B) The mAb was conjugated with MBI's dual-payload linker and payloads (MMAE and DXD), resulting in a dual-payload ADC with an average DAR of 1.6 MMAE + 1.6 DXD.
Both ADCs achieved a conjugation efficiency of 80%.



Figure 4. Conjugation process monitoring of enzymatic conjugation

(A) Traditional ADC:

- Average DAR: 1.8-1.9 MMAE
- Conjugation efficiency: > 90%

(B) MBI's Dual-Payload ADC:

- Average DAR: •1.8-1.9 MMAE + 1.8-1.9 DXD
- Conjugation efficiency : **> 90%**

(A) A mAb was conjugated with a traditional linker and MMAE, yielding an ADC with an average Drug-to-Antibody Ratio (DAR) of 1.8-1.9.
(B) The mAb was conjugated with MBI's dual-payload linker and payloads (MMAE and DXD), resulting in a dual-payload ADC with an average DAR of 1. 8-1.9 MMAE + 1.8-1.9 DXD.
Both ADCs achieved a conjugation efficiency exceeding 90%.

The linker can be further modified to accommodate various conjugation strategies, offering enhanced flexibility for broader applications and meeting the diverse requirements of CDMO clients.

Efforts will continue to demonstrate the ideal, driving the development of new conjugation strategies and creating new-drug opportunities.

We welcome interested companies to contact us for further details.